Rationale and Design of the Carvedilol or Metoprolol European Trial in Patients with Chronic Heart Failure: COMET
Key result
The COMET trial enrolled 3029 patients with chronic heart failure to compare the effects of carvedilol versus metoprolol on morbidity and mortality, with follow-up until 1020 fatal events occur.
Why the study?
Does carvedilol compared to metoprolol tartrate improve morbidity and mortality in patients with chronic heart failure?
Population
3029 patients with chronic heart failure from 15 different European countries
Comparison
Carvedilol (target dose 25 mg bid) vs Metoprolol tartrate (target dose 50 mg bid)
Design
Other
Follow-up
until 1020 fatal events have been observed
Authors
Discussion
Loading...
Member takes
Implication
COMET RCT directly compares carvedilol versus metoprolol in chronic HF; extends prior beta-blocker evidence via head-to-head design.
Study Design
Type
RCT (n=3,029)
Multicenter
Yes
Structured PICO
Does carvedilol compared to metoprolol tartrate improve morbidity and mortality in patients with chronic heart failure?
P
Population
3029 patients with chronic heart failure from 15 different European countries
I
Intervention
Carvedilol (target dose 25 mg bid)
C
Comparator
Metoprolol tartrate (target dose 50 mg bid)
O
Outcome
Morbidity and mortality (followed until 1020 fatal events have been observed)hard clinical
This paper outlines the rationale and design of the COMET trial, which compares the effects of carvedilol versus metoprolol tartrate on morbidity and mortality in chronic heart failure.
Cite This Study
Poole‐Wilson et al. (2002) conducted an RCT in chronic heart failure (n=3,029). carvedilol vs. metoprolol tartrate 50 mg bid was evaluated on morbidity and mortality. The COMET trial enrolled 3029 patients with chronic heart failure to compare the effects of carvedilol versus metoprolol on morbidity and mortality, with follow-up until 1020 fatal events occur.